Sirt1/Nrf2 signalling pathway prevents cognitive impairment in diabetic rats through anti-oxidative stress induced by miRNA-23b-3p expression

JINHUA HAN1, XIAONING LIU2, YINGZHI LI2, JUN ZHANG2 and HAICHI YU2

Departments of 1Radiotherapy and 2Orthopaedics, The Second Hospital of Jilin University, Changchun, Jilin 130021, P.R. China

Received July 23, 2017; Accepted December 12, 2017

DOI: 10.3892/mmr.2018.8876

Abstract. In the present study the exact roles and mechanisms underlying the effect of miRNA-23b-3p on the cognitive impairment of diabetic rats were investigated. The in vivo model of diabetes was established in Wistar rats via a single injection of streptozotocin (STZ). Cognitive function was evaluated using a Morris water maze test. Oxidative stress was measured using ELISA kits, and the protein expression levels of B-cell lymphoma 2-associated X protein, silent information regulator 1 (SIRT1), nuclear factor erythroid 2-related factor 2 (Nrf2) and GAPDH were measured by western blot analysis. Micro (mi)RNA-23b-3p mimics were employed to increase miRNA-23b-3p expression in the in vitro model. Overexpression of miRNA-23b-3p increased oxidative stress (as indicated by the levels of glutathione peroxidase, glutathione, superoxide dismutase and malondialdehyde) and apoptosis in neurocytes following high-glucose treatment. The overexpression of miRNA-23b-3p also suppressed SIRT1 and Nrf2 expression in neurocytes following high-glucose treatment; it also promoted the SIRT1-induced inhibition of apoptosis and oxidative stress. The promotion of SIRT1 also decreased the effect of miRNA-23b-3p on cognitive impairment in diabetic rats. In conclusion, miRNA-23b-3p prevents the cognitive impairment of diabetic rats via anti-oxidative stress effects and the Sirt1/Nrf2 signaling pathway.

Introduction

The rapid development of human society and economy has rendered great changes in people's ways of work and life (1). Factors such as aging of social population, obesity, unhealthy living habits and heredity, have given rise to the gradually increased morbidity of diabetes mellitus (DM) (2). DM has become one of the global public health problems severely threatening human health after cardiovascular disease and tumor (2). According to the International Diabetes Federal (IDF) statistics, the world has witnessed approximately 0.246 billion DM patients in 2007 (1). Such fig. will increase to 0.380 billion by 2025 if no comprehensive control measure is carried out. DM epidemiological investigation in China in 1980 and 1994 suggested that DM morbidity in adult was 0.9 and 2.5%, respectively (3). DM is associated with long course of disease, many complications and high medical expenses, which has greatly affected the patients and the society (4). At present, non-infectious diseases dominated by DM, tumor and cardiovascular disease have become the major causes of global death (5). Therefore, carrying out research on the prevention and treatment of DM and its complications is of great social significance (5). Disorder of sugar, lipid and protein metabolism will induce systemic pathophysiological damage in multiple systems, tissues and organs (5). Moreover, it will also lead to complications in organs like eye, kidney, heart and brain (5). Of them, nervous system complications are the most common, such as DM neuropathy (5). At present, numerous reports regarding DM peripheral neuropathy are available from domestic and foreign medical scientific research (6). Particularly, DM cognitive impairment induced by DM central nervous system injury has been extensively studied.

Silent information regulator 1 (SIRT1) is a nicotinamide adenine dinucleotide (NAD+)-dependent histone deacetylase (7). It can act on histone and multiple non-histones, thus being involved in multiple physiopathological processes like anti-inflammation, anti-oxidative stress, anti-apoptosis and anti-cell aging (8).

miRNA is a big family of small molecule non-coding single-strand RNA with the length of approximately 20-25 basic groups (9). It is formed by a segment of single-strand RNA precursor with hairpin loop structure, which is 70-90 basic groups in length, after Dicer digestion (9). It can regulate gene expression at transcription level or post-transcription level (10). miRNA can bind with the 3'untranslated region
(UTR) of target message RNA (mRNA), thus exerting its function (10). In addition, it can result in transcription inhibition, and mRNA instability or degradation, and thus affect the pathophysiological processes of diseases (11).

Plenty of miRNAs have been discovered in brain tissue of mammals at present (10). They are related to brain tissue development, neuronal differentiation and senior neurological functions (such as learning and memory) (6). Moreover, they are also associated with diseases like neurodegenerative disease, mental disorder and brain tumor (6). As is found in recent research, miRNAs are also involved in regulating neuron cell cycle control and apoptosis in Alzheimer’s disease (AD) and Parkinson’s disease (PD) (12). Besides, they also participate in regulating the pathological process of post-ischemic brain injury (12). In this report, we investigated the exact roles and mechanisms of miRNA-23b-3p on cognitive impairment of diabetic rats.

Materials and methods

Animals. Firstly, male 8-week-old Wistar rats (180-220 g) were purchased from the Laboratory Animal Center of Jilin University and housed in standard laboratory cages at 22-24°C with a 12-h light/dark cycle and were provided free access to food and water. The experimental animals were randomly divided into two groups, the control group (n=6) and the DM group (n=6). DM model group, Wistar rats were induced via a single injection of 50 mg/kg streptozotocin (STZ; Sigma-Aldrich, Merck KGaA, Darmstadt, Germany) into the left lower abdominal cavity. On 8 week after STZ injection, the rats were anaesthetised with sodium pentobarbital (35 mg/kg, intraperitoneally; Beijing Propbs Biotechnology, Co., Ltd., Beijing, China). All experimental protocols and procedures were approved by the Animal Care and Ethics Committee of The Second Hospital of Jilin University (Jilin, China).

Next, 18 rats were randomly divided into three groups, the control group (n=6), the DM group (n=6) and SIRT1 group (n=6). SRT1720, rats was anaesthetised with 35 mg/kg sodium sodium pentobartal and sacrificed by decollation (13). Then, brain tissue samples were separated and hippocampus was stripped as reference (14). Hippocampus was fixed by 4% paraformaldehyde (paraformaldehyde) for 24 h, and sample was cleared with xylene and routinely embedded in paraffin. Tissue was cut into Serial coronal sections (10 µm), and then deparaffinised, rehydrated and then stained with H&E at room temperature for 15 min. Samples were observed via light microscopy (Olympus, Tokyo, Japan).

RNA extraction for microRNA expression analysis. Total RNA was extracted from PC12 cells or hippocampus tissue using miRNeasy® Mini kit (Qiagen GmbH, Hilden, Germany). 500 ng total RNA was changed to cDNA by miScript II RT kit (Qiagen, Inc., Valencia, CA, USA). QuantiTect SYBR Green PCR Master (Qiagen, Inc.) was used to Qpcr using a 7900HT thermocycler (Applied Biosystems; Thermo Fisher Scientific, Inc., Waltham, MA, USA). Qpcr were as follows: 50°C for 2 min, 95°C for 10 min, followed by a third step for denaturation at 95°C for 15 sec and at 60°C for 1 min repeated for 40 cycles. Data were presented as fold change in expression and were calculated as 2⁻⁵⁰.'
(50 µg) were separated via 8-12% (w/v) SDS-PAGE and transferred onto PVDF membranes. The membranes were blocked in PBST buffer containing 5% (w/v) skimmed milk for 1 h at 37˚C and incubated with Bax (sc-493, 1:500; Santa Cruz Biotechnology, Inc., Dallas, TX, USA), Sirt1 (sc-15404, 1:500; Santa Cruz Biotechnology, Inc.), nuclear factor erythroid 2-related factor 2 (Nrf2; sc-722, 1:500; Santa Cruz Biotechnology, Inc.) and GAPDH (sc-25778, 1:500; Santa Cruz Biotechnology, Inc.) overnight at 4˚C. The membranes were then incubated with the corresponding horseradish peroxidase-conjugated secondary antibody (7074, 1:5,000; Cell Signaling Technology, Inc., Danvers, MA, USA) at 37˚C for 1 h. The protein levels were measured using ECL kit (Bio-Rad Laboratories, Inc.) and quantified using Quantity One software version 4.62 (Bio-Rad Laboratories, Inc.).

Statistical analysis. All values are expressed as the mean ± standard deviation. One-way analysis of variance followed by Dunnett’s t-test was used for comparison between the groups. A two-tailed value of P<0.05 was considered to indicate a statistically significant value.

Results

miRNA-23b-3p expression. In order to analyze the change levels of miRNA-23b-3p in cognitive impairment of diabetic rats, it may be a importance role for cognitive impairment of diabetic or neurocyte cell apoptosis. As shown in Fig. 1, miRNA-23b-3p expression was up-regulated, and neurocyte appeared dearth in cognitive impairment of diabetic rats, compared with normal control group.

Overexpression of miRNA-23b-3p increased apoptosis in neurocytes following high glucose treatment. (A) miRNA-23b-3p expression, and levels of (B) cell proliferation and (C) apoptosis in neurocytes following high-glucose treatment. "P<0.01 vs. control group. Control, negative control group; miR-23b-3p, overexpression of microRNA-23b-3p group.

Overexpression of miRNA-23b-3p increased oxidative stress in neurocyte cell by high-glucose. Meanwhile, overexpression of miRNA-23b-3p also increased oxidative stress in neurocyte cell by high-glucose, compared with control group, which miRNA-23b-3p may mediated oxidative stress to induce neurocyte cell apoptosis (Fig. 4).
We detected SIRT1 and Nrf2 protein expression to explore the mechanism of miRNA-23b-3p on oxidative stress, SIRT1 and Nrf2 protein expression were measured. Overexpression of miRNA-23b-3p suppressed SIRT1 and Nrf2 protein expression in neurocyte cell by high-glucose (Fig. 5). These results support the theory that miRNA-23b-3p an oncogene that may contribute to oxidative stress in neurocyte cell by high-glucose.

In vitro model of neurocyte cell by high-glucose, the promotion of SIRT1 induced SIRT1 and Nrf2 protein expression. SRT1720, SIRT1 agonist, 10 µM for 48 h, was added into cell following miRNA-23b-3p, and SIRT1 and Nrf2 protein expression were measured. Fig. 6 showed that SIRT1 agonist induced SIRT1 and Nrf2 protein expression in neurocyte cell by high-glucose following miRNA-23b-3p, compared with miRNA-23b-3p group.

In vitro model of neurocyte cell by high-glucose, the promotion of SIRT1 inhibited apoptosis. Then, in vitro model of neurocyte cell by high-glucose, the promotion of SIRT1 inhibited the suppression of cell proliferation, and activation of apoptosis rate, Bax and caspase-3 activity in neurocyte cell by high-glucose following miRNA-23b-3p, compared with miRNA-23b-3p group (Figs. 7 and 8).

In vitro model of neurocyte cell by high-glucose, the promotion of SIRT1 inhibited oxidative stress. Additionally, the promotion of SIRT1 inhibited the activation of MDA level, and inactivation of GSH, GSH-PX, and SOD levels in neurocyte cell by high-glucose following miRNA-23b-3p, compared with miRNA-23b-3p group (Fig. 9). In vitro model of neurocyte cell by high-glucose, the promotion of SIRT1 inhibited oxidative stress, which may be regulated by high-glucose to generate cognitive impairment of diabetic rats.

In vivo of diabetic rats, the promotion of SIRT1 induced SIRT1 and Nrf2 protein expression. So, we used vivo of diabetic rats to determine the function of SIRT1 on cognitive impairment of diabetic rats. SRT1720, SIRT1 agonist, 50 mg/kg, 4 weeks, induced SIRT1 and Nrf2 protein expression in diabetic rats, compared with DM rat (Fig. 10).
In vivo of diabetic rats, the promotion of SIRT1 inhibited apoptosis and oxidative stress. The promotion of SIRT1 inhibited the activation of apoptosis rate, Bax and caspase-3/9 activity, and the induction of MDA level, and inhibition of GSH, GSH-PX, and SOD levels in diabetic rats, compared with DM rat (Figs. 11 and 12).

In vivo of diabetic rats, the promotion of SIRT1 prevents cognitive impairment. In order to assess the effect of SIRT1 on cognitive impairment of diabetic rats, Morris water maze test was used to measure. As showed in Fig. 13A and B, the promotion of SIRT1 reduced shorter escape latency and the mean path length in diabetic rats, compared with DM rat.
Figure 8. An in vitro model of neurocytes with high glucose treatment and the promotion of SIRT1-induced inhibition of Bax protein expression and caspase-3 activity. (A) Caspase-3 activity, and (B) Bax protein expression determined by (C) western blot analysis. **P<0.01 vs. control group; ##P<0.01 vs. miR-23b-3p group. Control, negative control group; miR-23b-3p, overexpression of microRNA-23b-3p group; miR-23b-3p+SIRT1, miRNA-23b-3p overexpression and SRT1720 (SIRT1 agonist) group; SIRT1, silent information regulator 1; Bax, B-cell lymphoma 2-associated X protein.

Figure 9. An in vitro model of neurocytes with high glucose treatment and the promotion of SIRT1-induced inhibition of oxidative stress. Levels of (A) GSH-PX, (B) GSH activity, (C) SOD activity and (D) MDA content. **P<0.01 vs. control group; ##P<0.01 vs. miR-23b-3p group. Control, negative control group; miR-23b-3p, overexpression of microRNA-23b-3p group; miR-23b-3p+SIRT1, miRNA-23b-3p overexpression and SRT1720 (SIRT1 agonist) group; SIRT1, silent information regulator 1; GSH-PX, glutathione peroxidase; GSH, glutathione; SOD, superoxide dismutase; MDA, malondialdehyde.

Figure 10. An in vivo model of diabetes in rats and the promotion of SIRT1-induced SIRT1 and Nrf2 protein expression. (A) SIRT1 and (B) Nrf2 protein expression were determined by (C) western blot analysis. **P<0.01 vs. control group; ##P<0.01 vs. DM group. Control, negative control group; DM, diabetic rat group; SIRT1, silent information regulator 1; SIRT1, silent information regulator 1, agonist SRT1720 treatment group; Nrf2, nuclear factor erythroid 2-related factor 2.
Figure 11. An in vivo model of diabetes in rats and the promotion of SIRT1-induced inhibition of apoptosis. (A) Caspase-3 activity, and (B) Bax protein expression determined by (C) western blot analysis. **P<0.01 vs. control group; ##P<0.01 vs. DM group. Control, negative control group; DM, diabetic rat group; SIRT1, silent information regulator 1, agonist SRT1720 treatment group; Bax, B-cell lymphoma 2-associated X protein.

Figure 12. An in vivo model of diabetes in rats and the promotion of SIRT1-induced inhibition of oxidative stress. Levels of (A) GSH-PX, (B) GSH activity, (C) SOD activity and (D) MDA content. **P<0.01 vs. control group; ##P<0.01 vs. DM group. Control, negative control group; DM, diabetic rat group; SIRT1, silent information regulator 1, agonist SRT1720 treatment group; GSH-PX, glutathione peroxidase; GSH, glutathione; SOD, superoxide dismutase; MDA, malondialdehyde.

Figure 13. An in vivo model of diabetes in rats and the promotion of SIRT1 associated prevention of cognitive impairment. (A) The escape latency, (B) mean path length, (C) the percentage of time spent in the target quadrant and (D) the number of times the animals crossed the former platform location. **P<0.01 vs. control group; ##P<0.01 vs. DM group. Control, negative control group; DM, diabetic rat group; SIRT1, silent information regulator 1, agonist SRT1720 treatment group.
Meanwhile, DM rats spent less time in the target quadrant and the number of times the animals crossed the former platform location were increased by the promotion of SIRT1, compared with DM rat (Fig. 13C and D).

**Discussion**

DM is a chronic and lifelong disease. Patients should master DM monitoring knowledge and detect all indexes regularly (15). This has played a vital role in reducing the incidence of complications in DM patients, as well as DM disability and fatality rates (15). DM cognitive impairment is a complication characterized by DM-induced cognitive impairment, accompanying with intracerebral structural and pathophysiological changes (16). The study suggested that microRNA-23b-3p expression was up-regulated, and neurocyte appeared death in cognitive impairment of diabetic rats. In this study, we only used Morris water maze to analyze cognitive impairment, which is a limitation of the current study, and we will execute more tests to measure the changes of cognitive impairment in further study.

Some scholars have suggested renaming it as DM encephalopathy and DM-related cognitive decline (17). But no consensus has been reached so far. Its pathogenesis and pathophysiological changes remain unclear. Previous research on glucose toxicity, insulin signal disorder, unbalanced homeostasis, inflammation, oxidative stress injury, vascular disease, and hypothalamic-pituitary-adrenal axis abnormality, has attained certain progress (17). We found that overexpression of microRNA-23b-3p inhibited cell proliferation, and increased apoptosis, Bax protein expression and caspase-3 activity in neurocyte cell by high-glucose. Zhan et al indicate that that miR-23b-3p supplement may be a potential anabolic in kainic acid-induced seizure (18).

Oxidative stress refers to dysfunction of antioxidant defense system, which leads to excessive production of reactive oxygen species and reactive nitrogen species, thus leading to tissue and cell injury (17). Oxidative stress is indicated in research to participate in DM genesis and development. It can also induce reduced nerve conduction velocity and promote neuronal apoptosis in DM mice (4). This suggests that oxidative stress is involved in DM-induced neuronal injury (4). In the present study, overexpression of microRNA-23b-3p also increased oxidative stress in neurocyte cell by high-glucose. Jiang et al reported that microRNA-23b-3p up-regulate reactive oxygen species (ROS) and oxidative stress in acute myeloid leukemia (19).

Oxidative stress is a pathological state caused by excessive production of oxygen free radical (17). This has given rise to excessive accumulation of oxygen free radical and related metabolites, thus producing all kinds of cytotoxicities (20). The occurrence of oxidative stress can also induce cell aging. SIRT1 has been verified to exert antioxidation through regulating the transcription activity of some key enzymes (21).

SIRT1 can protect pancreas islet β cell, regulate insulin release, improve insulin resistance, reduce inflammatory response and regulate lipid metabolism (22). Thus, it can participate in regulating glucose homeostasis and thereby inhibit DM and DM-induced organ dysfunction (7). SIRT1 is indicated in research to alleviate DM genesis and DM-induced complications (23). Therefore, SIRT1 may become a target for treating insulin resistance and type 2 DM (23). The results showed that Overexpression of miRNA-23b-3p suppressed SIRT1 and Nrf2 protein expression in neurocyte cell by high-glucose. Zhao et al identified that miR-23b-3p induces the cellular metabolic memory of high glucose via SIRT1 pathway in diabetic retinopathy (24).

Nrf2 is the most important transcription factor for cell to regulate antioxidant stress response (24). Nrf2 activation is the precondition to exert its function (25). In contrast, Nrf2 dissociation with Keap1 is the first step for it to regulate target gene transcription (26). Under physiological status, binding of Nrf2 with cytoplasmic partner Keap1 is relatively inhibited. Two cysteine sites on Keap1, C273 and C288, are simultaneously modified under the action of oxidative stressor. This has resulted in coupling of Keap1 with Nrf2 (26). Meanwhile, the ubiquitination of ubiquitinating enzyme on Nrf2 is weakened or eliminated (27). This leads to uncoupling of Nrf2 with Keap1, followed by nuclear translocation. Nrf2 then binds with the antioxidant response element ARE (27). Subsequently, it initiates the downstream antioxidant gene and expression of phase-II detoxifying enzyme (27). Thus, it enhances cell resistance to oxidative damage (28). Downstream antioxidant enzyme expression is reduced in the presence of disordered or deleted Nrf2 activation (29). Thus, it cannot act against toxicity of antioxidant stressor on cell. Consequently, it will lead to cell dysfunction, apoptosis or necrosis (29). We also showed that the promotion of SIRT1 inhibited apoptosis and oxidative stress, decreased the microRNA-23b-3p on cognitive impairment of diabetic rats via Nrf2 expression. Zhao et al showed that miR-23b-3p induces the cellular metabolic memory through a SIRT1-dependent signalling pathway in diabetic retinopathy (24). However, we only used Western blot to analyze the protein expression of SIRT1 by miR-23b-3p, which is a limitation of the current study, and we will execute more tests to measure the changes of SIRT1 and Nrf2 in further study.

In conclusion, the above histopathological and molecular biological results suggested that the Sirt1/Nrf2 signalling pathway is involved in oxidative stress-induced apoptosis and caused cognitive impairment in of diabetic rats through miR-23b-3p. Enhancing Sirt1/Nrf2 signalling pathway activity or the inhibition of miR-23b-3p may serve as a potential therapeutic strategy for cognitive impairment in diabetic.

**References**


